| Related Articles |
Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors.
Br J Cancer. 2018 Dec 11;:
Authors: Bertolini F
Abstract
Immune checkpoint inhibitors have shown unprecedented clinical activity in a variety of cancer types, but only in a fraction of patients. Promising in vivo synergies have been demonstrated between checkpoint inhibitors and other drugs and/or chemotherapy or radiotherapy, and effective models are now needed to select the best combinatorial regimen and disease setting.
PMID: 30538261 [PubMed - as supplied by publisher]
from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2C92giT
No comments:
Post a Comment